IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Alexion Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm

LOS ANGELES--()--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (Nasdaq: ALXN) concerning possible violations of federal securities laws.

To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at brian@lundinlawpc.com.

On November 9, 2016, Alexion announced that is investigating accusations of improper sales practices of its top drug, Soliris, which is estimated to account for 92% of the Company’s sales for 2016. The Company retained outside counsel and announced its decision to delay its third-quarter financial report.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

Contacts

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/